ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2812

Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile

Erkan Kilic1, Cagri Sakalar2, Huriye Aksu3, Mustafa Cakir3, Gamze Kilic1 and Salih Ozgocmen4, 1Dept. PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey, 2Genome and Stem Cell Center (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, 3Genome and Stem Cell Senter (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, 4Dept.PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS), axial spondyloarthritis, cytokines and monocytes, Immune regulation

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial spondyloarthritis
(axSpA) defines a group of chronic inflammatory diseases which includes non-radiographic
axSpA (nr-axSpA) who do not have definite sacroiliitis on pelvic X-rays. Disease
burden seems to be similar between nr-axSpA and AS, however differences or similarities
in disease progress and pathogenesis are not completely clear.  Thymoquinone (TQ) is
the active ingredient of Nigella sativa and it’s anti-inflammatory,
anticancer and immunoregulatory role has been demonstrated
in various diseases. The aim of this study was to investigate the cytokine production
of peripheral blood mononuclear cells (PBMC) in pts with axSpA (AS and
nr-axSpA) and the effect of thymoquinone on the
cytokine profile.

Methods: Pts with axSpA
who met the ASAS axSpA classification criteria and age-matched healthy controls
(HC) were enrolled in this study. Pts were DMARD naive (biologic or synthetic),
and 23 pts were using only NSAIDs (19 on demand, 5 regular full dose). All of
the pts had pure axial involvement and none had peripheral arthritis or
psoriasis or IBD. Peripheral blood mononuclear cells (PBMCs) were cultured in
RPMI medium with and without TQ (12.5 µM ). PBMCs were
stimulated for 48 hours with 10 µg/ml phytohemagglutinin
and secretion of TNF-
α, interleukin-4 (IL4), IL6, IL8, IL10, IL17 and VEGF was measured in the
supernatant by ELISA (lab investigators were blind to pts/controls clinical
diagnosis/variables).

Results: Twenty-nine pts
with axSpA (14 male, 37.2±12.6 yrs) and age- and gender-matched 14 healthy
controls (7 male, 35.6±9.6 yrs) were included. In axSpA group 15 pts were
nr-axSpA (mean symptom duration; 5.3±6.7 yrs) and 14 pts were AS (10.4±8.6 yrs).
Disease activity assessed by BASDAI and ASDAS-CRP were similar in pts with AS
(4.4±2.3 and 2.9±1.3) and nr-axSpA (3.8±1.9 and 2.6±1.1). Cytokine levels
without TQ are given in Table 1. Interleukin-4 (Il-4), Il-8, TNF-α and VEGF were significantly different in pts with axSpA
compared to HCs. Cytokine profiles were similar in pts with AS and nr-axSpA. TQ supressed cytokine secretion in pts
with axSpA and HCs (Table 2).
However VEGF secretion increased with TQ,
particularly in pts with AS (nr-axSpA 18.4±5.1 vs AS 29.1±13.2 pg/ml, p=0.011).

Conclusion: This is the first study reporting similar cytokine profile of stimulated
PBMCs in patients with AS and nr-axSpA and the suppressive effect of TQ on
cytokine production of PBMCs. Also our results showed increased production of VEGF
by PBMCs despite TQ particularly in patients with AS.  

Acknowledgement: This
study is supported with a grant from Scientific Research Projects Unit of our
university TTU-2013-4890. 

  

Table 1. Cytokine levels between axial spondyloarthritis and healthy controls (HCs) (pg/ml, mean±SEM)

HCs (n=14)

axSpA (n=29)

P

AS(n=14)

p

nr-axSpA (n=15)

p

IL-4

226.7 ± 12.8

203.5 ± 18. 2

0.022

216.2 ± 33.3

0.250

191.7 ± 17.3

0.060

IL-6

1906.8 ± 305.8

2806.1 ± 420.3

0.328

3667.5 ± 688.5

0.054

2002.2 ± 420.6

0.694

IL-8

13095.2± 2063.9

26257 ± 859.1

˂0.0001

26908.2 ± 719.0

˂0.0001

25649.3 ± 1533.3

˂0.0001

IL-10

1091.2 ± 233.2

1641.8 ± 52.2

0.106

1686.4 ± 306.7

0.108

1600.2 ± 275.3

0.163

IL-17

432.5 ± 84.8

350.1 ± 40.7

0.857

319.6 ± 50.6

0.383

378.6 ± 63.8

0.777

TNF-α

739.9 ± 77.4

578.1 ± 52.2

0.009

506.4 ± 56.55

0.029

645.0 ± 84.3

0.432

VEGF

6.9 ± 3.1

20.6 ± 4.6

0.001

27.0 ± 8.7

0.001

14.6 ± 3.5

0.007

Table 2. Comparisons of cytokine levels with and without thymoquinone in HCs and axSpA (pg/ml, mean±SEM)

pg/ml

mean±SEM

HCs+TQ (n=14)

HCs vs HCs+TQ

p

axSpA+TQ(n=29)

axSpA vs axSpA+TQ

p

IL-4

159.5 ± 7.5

0.002

190.7 ± 8.6

0.754

IL-6

31.8 ± 2.9

0.001

24.7 ± 4.5

0.002

IL-8

357.4 ± 19.9

0.001

679.4 ± 273.8

0.002

IL-10

5.2 ± 1.7

0.001

3.3 ± 0.8

0.002

IL-17

9.6 ± 4.3

0.001

7.1 ± 2.4

0.002

TNF -α

246.6 ± 12.3

0.001

270.1 ± 17.54

0.002

VEGF

18.0 ± 4.5

0.002

23.6 ± 2.1

0.859


Disclosure: E. Kilic, None; C. Sakalar, None; H. Aksu, None; M. Cakir, None; G. Kilic, None; S. Ozgocmen, None.

To cite this abstract in AMA style:

Kilic E, Sakalar C, Aksu H, Cakir M, Kilic G, Ozgocmen S. Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cytokine-secretion-by-peripheral-blood-mononuclear-cells-in-patients-with-axial-spondyloarthritis-and-the-effect-of-thymoquinone-on-cytokine-profile/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokine-secretion-by-peripheral-blood-mononuclear-cells-in-patients-with-axial-spondyloarthritis-and-the-effect-of-thymoquinone-on-cytokine-profile/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology